TRIMERBODY PHARMA
Contact information
- Biodrugs
- Drug development
- Drug discovery
- Immunology
- Oncology
Trimerbody Pharma is a biotechnology company specialized in the development of innovative immunotherapies for the treatment of cancer. Our proprietary technology platform, Trimerbody®, enables us to design next-generation bispecific oncology antibodies that effectively and safely enhance the body’s immune response, simultaneously targeting tumor cells and effector T lymphocytes.
Our multidisciplinary and highly experienced team is dedicated to transforming the landscape of cancer immunotherapy and making a significant contribution to improving the quality of life of patients with advanced solid tumors. The Trimerbody format has been specifically designed to provide enhanced properties for therapeutic applications, particularly in the field of immuno-oncology.
LEAD-452, our most advanced candidate, is a next-generation bispecific agonist antibody targeting 4-1BB, in the Trimerbody format. It specifically directs its agonist activity toward the EGFR-associated tumor antigen at the tumor site, while limiting such activity in healthy tissues, thereby reducing immunotoxicity.
In preclinical studies, LEAD-452 has demonstrated a strong antitumor response without the adverse effects commonly associated with conventional immunostimulatory therapies, such as liver inflammation or cytokine release syndrome.
Biopharmaceutical companies developing oncology or immunomodulatory therapies, biotechnology companies specialized in antibody platforms or complementary technologies, molecular diagnostics and personalized medicine companies, investment funds, big pharma, CDMOs, CROs, etc.